Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
GDFATHER-NEO
Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer
- NCT06059547 ↗
- Completed
- CatalYm GmbH
- Deep
We haven't built an HCP commentary report on GDFATHER-NEO (nivolumab and visugromab in Bladder Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GDFATHER-NEO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 26 | |
| YouTube | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Bladder Cancer; Adult Solid Tumor
- Interventions
- Nivolumab; Visugromab (CTL-002); Placebo
- Arms
- Combination with Placebo · Active comparator
- Combination with Visugromab/Verum · Experimental
- Enrollment
- 31
- Primary outcomes
- Pathological complete response rate
- Radiological response rate according RECIST
- Sponsor
- CatalYm GmbH
- Start
- Sep 6, 2023
- Primary completion
- Oct 16, 2025
- Results posted
- No
- Registry record
- NCT06059547 · updated Aug 19, 2026
Publications
linked from the registry- Necchi A, Mercinelli C, Maiorano BA, Piacentini M, Cigliola A, Iacovelli R, Ciccarese C, Ligato C, Giannatempo P, Rametta A, Gontero P, Soria F, Schuberth-Wagner C, Wischhusen J, Rossler B, Metterlein M, Ries S, Ross T, Amin A, Dreker T, Hermann F, Lemke L, Klar K, Mitina O, Kamova A, Fettes P, Auckenthaler A, Rao S, Leo E, Lichtenegger FS. Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial. Nat Med. 2026 Oct 24. doi: 10.1038/s41591-026-04740-9. Online ahead of print. PubMed 42926233